Late Phase Cancer Division

What we do

Our work in Late Phase Cancer involves the design, conduct and analysis of large multi-centre academic phase II and III clinical trials, with a focus on drug and radiotherapy interventions in haematological and solid cancers.

Our trials compare interventions by looking at clinical effectiveness through survival, response to treatment, toxicity and patient-reported outcomes, and cost effectiveness.

Our trials are large randomised controlled trials, which compare two or more interventions including chemotherapy, radiotherapy, biological agents, or combinations of these. Our trials have innovative designs which efficiently evaluate novel interventions and evaluate personalised medicine approaches. Many of our trials are associated with translational research programmes which add to scientific knowledge and, alongside meta-analysis and exploratory analysis, provide evidence, hypothesis and insight which lead to the next generation of early and late phase clinical trials in cancer.

Our trials provide evidence which change clinical practice in the United Kingdom, Europe and worldwide.

Key publications

Key publications our team has contributed to

  1. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
    Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Study Group.
    Lancet. 2010 Dec 11;376(9757):1989-99. doi: 10.1016/S0140-6736(10)62051-X. Epub 2010 Dec 3.
  2. Breast-cancer adjuvant therapy with zoledronic acid.
    Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R; AZURE Investigators.
    N Engl J Med. 2011 Oct 13;365(15):1396-405. doi: 10.1056/NEJMoa1105195. Epub 2011 Sep 25.


Who we are


Division Director
Dr David Cairns

View our team members